Propranolol versus nadolol for treatment of pediatric subglottic hemangioma

The beta-blocker propranolol is the standard medical therapy for subglottic hemangioma (SGH), but side effects and incomplete response rates require close monitoring. Nadolol has been identified as a potential alternative but its use has not been examined for SGH. Single institution retrospective co...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pediatric otorhinolaryngology 2021-05, Vol.144, p.110688-110688, Article 110688
Main Authors: Yang, Weining, Wolter, Nikolaus E., Cushing, Sharon L., Pope, Elena, Wolter, Jennifer K., Propst, Evan J.
Format: Article
Language:English
Subjects:
Beta-blocker
Hemangioma
Infantile
Malformation
Nadolol
Propranolol
Stridor
Subglottic
Vascular
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The beta-blocker propranolol is the standard medical therapy for subglottic hemangioma (SGH), but side effects and incomplete response rates require close monitoring. Nadolol has been identified as a potential alternative but its use has not been examined for SGH. Single institution retrospective cohort study of pediatric SGH treated with propranolol or nadolol. Thirteen children (1 male, 12 female) with SGH were included: 6 were treated with propranolol (2.0–3.5 mg/kg/d) and 7 with nadolol (2.0–4.0 mg/kg/d). The most common presenting symptom was stridor (85%) and mean (SD) symptom duration prior to diagnosis was 4.6 (3.8) weeks. Cutaneous vascular lesions were present in 54%. There were 7 right-sided, 5 left-sided and 1 bilateral SGH. The mean (SD) percentage of airway obstruction was 60.6% (27.4). The response rate was 100% (6/6) for propranolol and 85.7% (6/7) for nadolol (p = 0.36). Mean (SD) time to symptomatic improvement was 2.6 (2.2) days with no difference across groups (p = 0.71). There was no hypotension, hypoglycemia, weight loss, or sleep disturbances in either group. One patient in the propranolol group experienced vomiting. Two patients in the nadolol group required dosage reduction due to asymptomatic bradycardia. The mean (SD) duration of admission was 14.4 (12.6) days and duration of treatment was 13.8 (11.2) days with no difference across groups (p = 0.23; p = 0.31, respectively). All patients had treatment initiated as inpatients and completed as outpatients. Children with SGH treated with propranolol or nadolol had similar response rates and side effect profiles.
ISSN:0165-5876
1872-8464
DOI:10.1016/j.ijporl.2021.110688